CardioSource WorldNews | Page 48

*1-11

IMPORTANT SAFETY INFORMATION (cont’d)
OVERDOSAGE
Discontinue XARELTO® and initiate appropriate
therapy if bleeding complications associated with
overdosage occur. A specific antidote for rivaroxaban is
not available. The use of activated charcoal to reduce

absorption in case of XARELTO® overdose may be
considered. Due to the high plasma protein binding,
rivaroxaban is not expected to be dialyzable.

ADVERSE REACTIONS IN CLINICAL STUDIES
The most common adverse reactions with
XARELTO® were bleeding complications.

038573-150812

Published safety outcomes in real-world patients,
from observational studies

*Based on the following registries, claims databases, and studies: Optum Labs=16,253; IMS Health LifeLink=1,649; Truven Health=5,563; Danish registry=1,303;
XAMOS=8,778; Symphony=3,654; ORTHO-TEP=1,043; Japanese registry=1,035; Dresden NOAC=1,776; DOD database=27,467; XANTUS=6,784.

Please see Important Safety Information on preceding pages.
Please see accompanying Brief Summary of full Prescribing Information, including Boxed WARNINGS, on preceding pages, or visit www.XareltoHCP.com/PI.
XARELTO® is licensed from Bayer HealthCare AG, 51368 Leverkusen, Germany.
© Janssen Pharmaceuticals, Inc. 2015
December 2015
039521-150831

Janssen Pharmaceuticals, Inc.